Plus Therapeutics Inc Stock

$0.31

10.08% yesterday

Nasdaq, Jun 13, 10:18 pm CET

ISIN

US72941H4002

Symbol

PSTV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Plus Therapeutics Inc Stock price

$0.31

-28.92 98.93% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

-0.04 10.08%

ISIN

US72941H4002

Symbol

PSTV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$10.27m
Enterprise Value	$400.00k
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.08
P/S ratio (TTM) P/S ratio	1.97
P/B ratio (TTM) P/B ratio	negative
Revenue growth (TTM) Revenue growth	-14.31%
Revenue (TTM) Revenue	$5.21m
EBIT (operating result TTM) EBIT	$-14.93m
Free Cash Flow (TTM) Free Cash Flow	$-12.87m
Cash position	$9.87m
EPS (TTM) EPS	$-1.86
P/E forward	negative
P/S forward	1.67
EV/Sales forward	0.07
Short interest	1.57%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Plus Therapeutics Inc forecast:

3x Buy

75%

1x Hold

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Plus Therapeutics Inc forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	5.21 5.21	14% 14% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	24% 24% 203%
- Research and Development Expense	9.57 9.57	1% 1% 184%
EBITDA	-14 -14	26% 26% -273%
- Depreciation and Amortization	0.71 0.71	15% 15% 14%
EBIT (Operating Income) EBIT	-15 -15	25% 25% -287%
Net Profit	-27 -27	130% 130% -521%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Plus Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

15 days ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today an...

Neutral

GlobeNewsWire

●

22 days ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (...

Neutral

GlobeNewsWire

●

about one month ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical com...

More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office	United States
CEO	Marc Hedrick
Employees	21
Founded	1996
Website	www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now